First study of galectin proteins with neutrons, guiding future drug development
Key binding characteristics of a sugar-binding protein associated with heart disease and breast cancer defined for the first time, guiding future drug development
- Researchers pinpoint hydrogen-bonding interactions in the C-terminal carbohydrate recognition domain of galectin-3 (galectin-3C) for the first time using neutron crystallography
- These detailed observations will inform future drug design for the treatment of diseases like heart disease, breast cancer and other inflammation diseases
Galectins attach to other proteins via the carbohydrates on their surfaces (sugar-binding proteins). As such they impact on a range of processes in the cell associated with a number of diseases, including heart disease and breast cancer – the most common cancer in women worldwide, with 1.7 million new cases diagnosed in 2012 alone.
Understanding how galectins bind to and distinguish between different sugars can help guide the design of new molecules that act as inhibitors – blocking this process, and therefore limiting the development of certain diseases. However, researchers are only beginning to get the full picture of the binding patterns involved and the exact details of the interactions between different sugars and the protein have not been well defined. Detailed knowledge of the hydrogen bond networks in the protein-sugar complexes is key to providing a better foundation in the efforts to design new effective galectin inhibitors.
In a collaborative effort, experts in neutron and X-ray crystallography from across Europe and the US came together to determine the hydrogen bonding networks in detail for the C-terminal carbohydrate recognition domain of galectin-3 (galectin-3C). Scientists from Institut Laue-Langevin (ILL, France), Lund University (Sweden), Oak Ridge National Laboratory (USA) and Heinz Maier-Leibnitz Zentrum (Germany) all worked together on the project.
Until now, much of our understanding of these binding processes has been guesswork since determining the positions of hydrogen atoms is extremely difficult using X-rays, due to the weak scattering of hydrogen with X-rays. Even in extremely high resolution X-ray crystallography experiments, only about half of the most ordered hydrogen atoms can be observed. Neutron crystallography, on the other hand, is an ideal technique to reveal the positions of hydrogen atoms and hence the geometry of hydrogen bonds, since hydrogen atoms scatter neutrons with approximately the same magnitude as the other elements of a protein (i.e. carbon, nitrogen, oxygen and sulphur). As such, the positions of hydrogen atoms are directly detected with neutrons rather than being inferred from the positions of heavier atoms as in X-ray crystallography.
Hydrogen bonds to lactose in the C-terminal carbohydrate recognition domain of galectin-3 as determined with neutron crystallography.
The bonds are represented here by light-blue dotted lines.
The resulting paper, published in Journal of Medicinal Chemistry, demonstrates that by using neutron crystallography the positions of the hydrogen atoms and the hydrogen bonding networks can be revealed, providing a better understanding of the binding interactions involved, even at modest resolutions. In addition, by determining the neutron structure of the sugar-free form of galectin-3C (apo galectin-3C) the positions and orientations of water molecules in the binding site before binding have been revealed. Hence comparison of the apo- and sugar-bound structures allowed us to observe how the interactions change upon binding and has helped improve our understanding of the role water plays in the binding process.
Matthew Blakeley, LADI-III beamline scientist at the ILL and co-author of the study, said: “Neutron crystallography is a powerful complementary technique to X-ray crystallography since it provides details relating to hydrogen atom positions which are generally not revealed using X-rays alone. Combining the information from both techniques therefore gives us the most detailed picture possible.”
Derek Logan, associate professor in structural biology at Lund University and main author of the study, said: “This experiment has helped to confirm that drug design against galectins to date has been wise to focus on molecules derived from sugars, as the interactions we see would be difficult to mimic with other molecular shapes. With this confirmation we are now in a much better position to accurately predict the key binding interactions and to help our colleagues in the pharmaceutical industry develop new drugs for use.”
Instrument: Quasi-Laue diffractometer LADI-III
Elucidation of hydrogen bonding patterns in ligand-free, lactose- and glycerol-bound galectin-3C by neutron crystallography to guide drug design,
Francesco Manzoni, Johan Wallerstein, Tobias Schrader, Andreas Ostermann, Leighton Coates,Mikael Akke, Matthew P. Blakeley, Esko Oksanen and Derek T. Logan
J Med Chem. 2018 May 24;61(10):4412-4420. doi: 10.1021/acs.jmedchem.8b00081
Contact at ILL:Dr Matthew Blakeley